[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f4kURly-cm2jdbnqXfKrnMST94CR8w2MhiQRm-nFkEE8":8,"$fMc6CjDVclxbuekphE3q_0J6h5ej7yu_p14v7hz8XnR8":55,"$fqDk1ZN9hLv-WRZFsm5JSy-27ZOV5Z9JCpzPXRpBtkhk":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},49190,868951,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//tSXHDQDwKYmcEBAQOrk1xetmaRm6ptR9.png","谭越","上海市闵行区肿瘤医院","肿瘤科","主治医师",20,0,"卵巢癌复发后的用药要点：高级别浆液性癌治疗药品全解","","https://ystcdn.venuertc.com/venue/AI/6e735745-342c-497e-99f7-55f12311bdfa.jpg","\u003Ch2 id=\"material_title\" class=\"ovarian_med_title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">卵巢癌复发后的用药要点：高级别浆液性癌治疗药品全解\u003C/h2>\n\n\u003Cdiv class=\"ovarian_med_intro\">\n  说到卵巢癌常用的药品，很多人听说过紫杉醇、卡铂，近年也有尼拉帕利、贝伐单抗、奥拉帕利等新型药物陆续应用。其实每种药物的成分、剂型、服用时间和注意事项都各有讲究。用得对，能提升疗效；用错了，风险很大。今天就带大家按7个细节，逐一讲清卵巢癌复发期药品的正确用法和关键注意事项，让每个用药都安心、更有把握。\n\u003C/div>\n\n\u003C!-- 01 紫杉醇和白蛋白紫杉醇用药要点 -->\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#fffce1 0%, #fafafa 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 紫杉醇和白蛋白紫杉醇：成分、剂型与作用机制\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">🔬\u003C/span>\u003C/div>\n  \u003Cp>\n    紫杉醇（Paclitaxel）是一种常用抗肿瘤药，主要通过稳定细胞微管、抑制细胞分裂来发挥抗癌作用。白蛋白紫杉醇（Abraxane, nab-paclitaxel）则是将紫杉醇结合到人血清白蛋白颗粒中，改良了溶剂，降低了部分过敏风险。\n  \u003C/p>\n  \u003Cul>\n    \u003Cli>剂型：紫杉醇为注射液，白蛋白紫杉醇也是静脉注射制剂。\u003C/li>\n    \u003Cli>规格：常见为每瓶100mg或260mg（具体以说明书为准）。\u003C/li>\n    \u003Cli>注意：这两种药只能由医疗机构静脉滴注给药。\u003C/li>\n  \u003C/ul>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#eaf7fc 0%, #fafafb 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 紫杉醇和白蛋白紫杉醇：正确用法用量\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">⏲️\u003C/span>\u003C/div>\n  \u003Cp>\n    这两种药物必须按体表面积个体化计算剂量，由医生配置后通过静脉点滴用药。一般每3周为一个周期，连续使用多周期。\n  \u003C/p>\n  \u003Cp>\n    正确做法：\u003Cbr>\n    - 用药期间按医嘱规律点滴，不能自行调整频率或剂量。\u003Cbr>\n    - 点滴速度需慢，通常3小时或更久，避免用药相关不良反应。\n  \u003C/p>\n  \u003Cp>\n    患者用药案例：一位57岁女性患者，使用化疗标准方案，紫杉醇和卡铂联合，出现血小板下降后，医生及时暂停并支持治疗，避免了出血风险。\n  \u003C/p>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#fff4e1 0%, #fafafa 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 紫杉醇和白蛋白紫杉醇：常见不良反应及处理\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">⚠️\u003C/span>\u003C/div>\n  \u003Cp>\n    常见副作用包括外周神经病变、骨髓抑制（白细胞、血小板减少）、恶心呕吐、脱发。白蛋白紫杉醇致过敏风险较低，但血小板下降同样需要密切监测。\n  \u003C/p>\n  \u003Cp>\n    出现异常（如出血点、持续高热等）应第一时间联系医生处理，不可继续自行用药。\n  \u003C/p>\n  \u003Cp>\n    数据表明，紫杉醇类化疗导致Ⅲ～Ⅳ级中性粒细胞减少的发生率可达60%以上\u003Cspan class=\"ovarian_med_refmark\">[McGuire, W.P., et al., N Engl J Med, 1996]\u003C/span>。\n  \u003C/p>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#e9fbe7 0%, #fafafa 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 卡铂和洛铂：剂型、使用和药物相互作用\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">💊\u003C/span>\u003C/div>\n  \u003Cp>\n    卡铂（Carboplatin）和洛铂（Lobaplatin）属于铂类抗肿瘤药，均为注射液，只有在医院内静脉滴注。\n  \u003C/p>\n  \u003Cul>\n    \u003Cli>剂量需根据体重和肾功能调整。\u003C/li>\n    \u003Cli>与其他骨髓抑制药联用时，副作用易叠加。\u003C/li>\n    \u003Cli>配伍静脉补液时，不得与含铝注射器具接触。\u003C/li>\n  \u003C/ul>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#f0edfd 0%, #f8f8fa 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 卡铂和洛铂：不良反应与特殊人群用药\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">🔔\u003C/span>\u003C/div>\n  \u003Cp>\n    用药易引起白细胞、红细胞、血小板减少；伴恶心、呕吐、肾功能损害等副作用。肾脏功能不良者须谨慎用药。\n  \u003C/p>\n  \u003Cp>\n    正确做法：开始期间需每周监测血常规及肾功能，必要时暂停化疗并给予支持治疗。\n  \u003C/p>\n  \u003Cp>\n    特殊人群调整：老年人剂量需下调，肝肾功能异常者须做个体化处理。\n  \u003C/p>\n  \u003Cp>\n    临床研究显示，联合化疗方案因骨髓抑制停药率约为15%\u003Cspan class=\"ovarian_med_refmark\">[Parmar, M.K., et al., Lancet, 2003]\u003C/span>。\n  \u003C/p>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#eaf5fe 0%, #f7f7fb 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 PARP抑制剂（尼拉帕利/奥拉帕利）：服用方法及特殊饮食要求\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">🕒\u003C/span>\u003C/div>\n  \u003Cp>\n    PARP抑制剂是一类新型靶向药，常用的尼拉帕利（Niraparib）、奥拉帕利（Olaparib）等，均为口服胶囊或片剂，用于卵巢癌的维持治疗。\n  \u003C/p>\n  \u003Cul>\n    \u003Cli>尼拉帕利通常每天同一时间服用，可空腹或随餐。\u003C/li>\n    \u003Cli>奥拉帕利建议分两次服用，餐前后均可，需整片吞服，不可嚼碎。\u003C/li>\n    \u003Cli>服药时应以一杯温水送服，不可与葡萄柚汁同用。\u003C/li>\n  \u003C/ul>\n  \u003Cp>\n    有患者服用尼拉帕利时，因自行调整剂量导致血小板下降，后经规范管理，症状明显改善。\n  \u003C/p>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#fff4e6 0%, #fafafa 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 PARP抑制剂：用药注意事项和常见不良反应\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">⚡\u003C/span>\u003C/div>\n  \u003Cp>\n    不良反应集中在消化道（如恶心、呕吐）、血液系统（低血红蛋白、白细胞及血小板减少）。少数人会感觉疲乏或食欲减退。长期服用需每月监测血常规。\n  \u003C/p>\n  \u003Cp>\n    正确做法：\u003Cbr>- 若出现严重乏力或异常出血，需及时和医生沟通，决不能自行加减药量。\u003Cbr>\n    - 不可与强CYP3A4抑制药（如某些抗真菌药）同时使用，防止药物堆积毒性风险。\n  \u003C/p>\n  \u003Cp>\n    数据显示，尼拉帕利≥3级血小板下降发生率约为33%\u003Cspan class=\"ovarian_med_refmark\">[Mirza, M.R., et al., N Engl J Med, 2016]\u003C/span>。\n  \u003C/p>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#e8f6e6 0%, #f9faf8 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 贝伐单抗：剂型、用法与禁忌\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">🚫\u003C/span>\u003C/div>\n  \u003Cp>\n    贝伐单抗（Bevacizumab）是重组人源化单克隆抗体注射液，属于靶向抗血管生成药，仅限在医院通过静脉慢滴使用。\n  \u003C/p>\n  \u003Cul>\n    \u003Cli>注射周期多数为每2-3周一次，滴注时间需大于90分钟。\u003C/li>\n    \u003Cli>禁忌患者包括有主动性出血、消化道穿孔、中重度高血压未控制者。\u003C/li>\n    \u003Cli>用药期间切勿进行大手术，术后恢复期未达28天严禁使用。\u003C/li>\n  \u003C/ul>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#f8f6e1 0%, #fbfaf8 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 贝伐单抗：常见不良反应及用药监测\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">🩸\u003C/span>\u003C/div>\n  \u003Cp>\n    贝伐单抗常见副作用包括高血压、蛋白尿、出血倾向、伤口愈合缓慢。\u003Cbr>\n    出现头痛、突发高血压、视力变化、皮肤出血点等需警惕。\n  \u003C/p>\n  \u003Cp>\n    正确用法：每次用药前测量血压、尿蛋白。如有异常，立即向医生报告，不得自行断药或减药。\n  \u003C/p>\n  \u003Cp>\n    临床数据表明，贝伐单抗联合化疗后，蛋白尿发生率9.3%-12.7%，高血压7.4%-15.8%\u003Cspan class=\"ovarian_med_refmark\">[Burger, R.A., et al., N Engl J Med, 2011]\u003C/span>。\n  \u003C/p>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#f4edff 0%, #f3f6fc 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 药物相互作用与联合用药\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">🔄\u003C/span>\u003C/div>\n  \u003Cp>\n    绝大部分化疗和靶向药物都存在药物间协同或相互干扰。\n  \u003C/p>\n  \u003Cul>\n    \u003Cli>紫杉醇不得与强CYP450抑制剂同用，否则代谢减慢，增加中毒风险。\u003C/li>\n    \u003Cli>铂类药如卡铂与氨基糖苷类抗生素合用时，肾毒性增强。\u003C/li>\n    \u003Cli>口服PARP抑制剂（如奥拉帕利、尼拉帕利）应避免与强CYP3A4抑制/诱导剂共用，否则药效可能增强或减弱。\u003C/li>\n  \u003C/ul>\n  \u003Cp>\n    正确做法：新联合用药、加用中草药、膳食补充剂前，务必咨询专业医生或药师。\n  \u003C/p>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#e9f7ef 0%, #f3faf6 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">11 漏服、过量处理与家庭药品储存\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">📦\u003C/span>\u003C/div>\n  \u003Cul>\n    \u003Cli>口服药物若漏服，应尽快补服一次，若接近下次服药时间，则跳过漏服部分，不可加量。\u003C/li>\n    \u003Cli>过量用药可能导致严重副作用，一旦出现应立即就医。\u003C/li>\n    \u003Cli>所有药品需妥善保存于儿童不可接触处，建议避光、常温、干燥处（除个别说明需冷藏者外）。\u003C/li>\n    \u003Cli>使用剩余注射剂可退回医院药房统一销毁，不可随意丢弃或堆放。\u003C/li>\n  \u003C/ul>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#f9f8e7 0%, #f7faf4 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">12 特殊人群与日常用药管理\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">👵\u003C/span>\u003C/div>\n  \u003Cp>\n    老年群体、肝肾功能不全、孕妇及哺乳期女性在用药时尤需谨慎，各自有专门调整原则。\n  \u003C/p>\n  \u003Cul>\n    \u003Cli>老年人用药前需做详细评估，化疗起始剂量建议下调，防止毒副反应。\u003C/li>\n    \u003Cli>肾功能减退时，铂类药物需严密监控，适量减量或延长用药间隔。\u003C/li>\n    \u003Cli>\u003Cstrong>孕妇、哺乳期妇女：几乎所有化疗及靶向药均为禁用或慎用。\u003C/strong>\u003C/li>\n  \u003C/ul>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#f5faff 0%, #f6fcf7 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">13 剂型选择与服药技巧\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">🏷️\u003C/span>\u003C/div>\n  \u003Cp>\n    紫杉醇、卡铂、贝伐单抗均为静脉注射制剂，无口服剂型，需由专业护士配制并严格监护。\n  \u003C/p>\n  \u003Cp>\n    口服药奥拉帕利、尼拉帕利等应整片吞下，忌嚼碎、研粉。服药时避免食用葡萄柚、葡萄柚汁，以免影响药效。\n  \u003C/p>\n  \u003Cp>\n    正确做法：\u003Cbr>\n    - 用足量温水送服，保证药片顺利下咽，降低食管刺激。\n  \u003C/p>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#e1f5ff 0%, #faf3f9 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">14 不可忽视的用药监测与再评估\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">🔍\u003C/span>\u003C/div>\n  \u003Cp>\n    化疗或靶向治疗期间，需定期监测血象、肝肾功能、电解质和血压。\n  \u003C/p>\n  \u003Cul>\n    \u003Cli>每次化疗或新药物开始后1周进行复查，以便及时发现骨髓抑制或器官损伤。\u003C/li>\n    \u003Cli>长期靶向药服用者，每月复查血常规。\u003C/li>\n    \u003Cli>用药期间如有任何不适、出血、感染迹象，建议暂停用药、及时就医。\u003C/li>\n  \u003C/ul>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#f8f7f4 0%, #fafaf7 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">15 合理用药总结与用药提醒\u003C/h2>\n  \u003Cdiv class=\"ovarian_med_iconline\">\u003Cspan class=\"ovarian_med_emoji\">📝\u003C/span>\u003C/div>\n  \u003Cp>\n    紫杉醇、铂类化疗药、PARP抑制剂、贝伐单抗等，是当前卵巢癌复发治疗中最常见的药物。它们各有成分差别和操作要求，既不能混淆自行使用，也不建议随意模仿他人剂量。\n  \u003C/p>\n  \u003Cp>\n    最重要的用药细节有两点：\u003Cbr>\n    1. 所有静脉化疗药都必须在医疗机构，由专业人员给药。\u003Cbr>\n    2. 口服药则应遵医嘱定期监测血象，绝不能随意停换、加减剂量。\n  \u003C/p>\n  \u003Cp>\n    如果用药期间遇到不良反应、其他疾病需加药，务必请医生、药师评估后处理。合理用药，是获得最大收益、减少风险的关键。\n  \u003C/p>\n\u003C/section>\n\n\u003Csection class=\"ovarian_med_section\" style=\"background: linear-gradient(90deg,#f6fdf6 0%, #fdfcf6 100%);\">\n  \u003Ch2 class=\"ovarian_med_h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献 References\u003C/h2>\n  \u003Col>\n    \u003Cli>\n      McGuire, W.P., Hoskins, W.J., Brady, M.F., et al. (1996). Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and IV Ovarian Cancer. \u003Cem>New England Journal of Medicine, 334\u003C/em>(1), 1-6.\n    \u003C/li>\n    \u003Cli>\n      Parmar, M.K., Ledermann, J.A., Colombo, N., et al. (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. \u003Cem>Lancet, 361\u003C/em>(9375), 2099-2106.\n    \u003C/li>\n    \u003Cli>\n      Mirza, M.R., Monk, B.J., Herrstedt, J., et al. (2016). Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. \u003Cem>New England Journal of Medicine, 375\u003C/em>(22), 2154-2164.\n    \u003C/li>\n    \u003Cli>\n      Burger, R.A., Brady, M.F., Bookman, M.A., et al. (2011). Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. \u003Cem>New England Journal of Medicine, 365\u003C/em>(26), 2473-2483.\n    \u003C/li>\n  \u003C/ol>\n\u003C/section>\n\n\u003Cstyle>\n.ovarian_med_title {\n  text-align:center;\n  margin: 55px 0 22px 0;\n  font-size: 2.2em;\n  font-family: \"Helvetica Neue\",Helvetica,Arial,sans-serif;\n  color:#963f31;\n  background: linear-gradient(90deg, #f0f6fd 0%, #f7ebe0 100%);\n  padding: 22px 0;\n  border-radius: 12px;\n  letter-spacing:1px;\n}\n\n.ovarian_med_intro {\n  font-size: 1.16em;\n  margin: 0 0 35px 0;\n  border-left: 7px solid #bdd3ea;\n  background: linear-gradient(90deg,#f6faff 0%,#fff4ed 100%);\n  padding: 18px 24px;\n  color:#6e735f;\n  border-radius: 8px;\n}\n\n.ovarian_med_section {\n  margin:22px 0 36px 0;\n  padding:30px 18px 28px 18px;\n  border-radius: 10px;\n  box-shadow: 0 1px 7px 2px #ececec;\n}\n\n.ovarian_med_h2 {\n  font-size:1.35em;\n  color:#574563;\n  margin-bottom:15px;\n  font-family: \"PingFang SC\",\"Microsoft Yahei\",Arial;\n  letter-spacing:0.9px;\n}\n\n.ovarian_med_iconline {\n  display:flex;\n  align-items:center;\n  margin-bottom:8px;\n}\n\n.ovarian_med_emoji {\n  font-size:1.5em;\n  margin-right:2px;\n}\n\n.ovarian_med_section ul,\n.ovarian_med_section ol {\n  margin-top: 13px;\n  margin-bottom: 10px;\n  padding-left: 25px;\n  font-size: 1.05em;\n}\n.ovarian_med_section ul li,\n.ovarian_med_section ol li {\n  line-height:1.9em;\n  margin-bottom: 3px;\n  color:#442A2B;\n}\n\n.ovarian_med_section p {\n  line-height: 1.92em;\n  margin-bottom: 5px;\n  font-size: 1.12em;\n  color:#424d39;\n  letter-spacing:0.05em;\n}\n\n.ovarian_med_refmark {\n  color: #A57045;\n  font-size:0.98em;\n}\n\n.ovarian_med_section strong {\n  color:#992d21;\n}\n\u003C/style>\n","\u003Ch2 id=\"material_title\" class=\"ovarian_med_title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0",577,"2025-07-15 15:19:46","卵巢癌, 紫杉醇, PARP抑制剂, 疗效, 不良反应, 用药注意事项, 化疗药, 靶向治疗","详细解读卵巢癌复发后常用药品，如紫杉醇、PARP抑制剂等，用药注意事项及不良反应，助您安全合理用药。","2025-07-17 06:02:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]